Considering the contrary activity by diverse pathways, including JAK1-STAT3, Tyk2-STAT2, JAK3-STAT5, etc. (Wu et al., 2016), the screening of selective inhibitors of JAKs may lead to the discovery of anti-gastric cancer drug candidates with lower side effects. This evidence concerns the gene TYK2 and gastric cancer.